Literature DB >> 12661761

The possible mechanism of action of ciclopirox olamine in the yeast Saccharomyces cerevisiae.

Sun-Hee Leem1, Jung-Eun Park, Il-Shin Kim, Ji-Youn Chae, Akio Sugino, Yangil Sunwoo.   

Abstract

Ciclopirox olamine is a synthetic antifungal agent with a high affinity for trivalent metal cations. Ciclopirox olamine can be used to synchronize mammalian cells, but its mechanism of action is not understood well. In this study, we investigated the effect of ciclopirox olamine in yeast cells and used a genetic approach to identify potential ciclopirox olamine targets in yeast. Wild type strains of the yeast Saccharomyces cerevisiae were weakly sensitive to ciclopirox olamine, but high concentrations of the drug arrested their growth at many different stages. MMS-mutagenized yeast clones were screened for increased sensitivity to ciclopirox olamine. Fourteen mutants, cos101-cos114, were identified and characterized. The targets of ciclopirox olamine in S. cerevisiae appear to include multiple proteins that participate in various components of cellular metabolism, including DNA replication, DNA repair, and cellular transport. Three genes were cloned: a Fe/Cu reductase (FRE1/COS107), an oxidative stress response gene (YAP1/COS110), and a gene involved in signal transduction (YBR203W/COS111). These results suggest that CPO inhibits multiple aspects of cell growth and metabolism, possibly via multiple targets.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12661761

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  13 in total

1.  Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK.

Authors:  Hongyu Zhou; Chaowei Shang; Min Wang; Tao Shen; Lingmei Kong; Chunlei Yu; Zhennan Ye; Yan Luo; Lei Liu; Yan Li; Shile Huang
Journal:  Biochem Pharmacol       Date:  2016-07-07       Impact factor: 5.858

Review 2.  Lessons from fungal F-box proteins.

Authors:  Wilfried Jonkers; Martijn Rep
Journal:  Eukaryot Cell       Date:  2009-03-13

3.  Fungicidal drugs induce a common oxidative-damage cellular death pathway.

Authors:  Peter Belenky; Diogo Camacho; James J Collins
Journal:  Cell Rep       Date:  2013-02-14       Impact factor: 9.423

Review 4.  Repositioning the Old Fungicide Ciclopirox for New Medical Uses.

Authors:  Tao Shen; Shile Huang
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

5.  The antitumor activity of the fungicide ciclopirox.

Authors:  Hongyu Zhou; Tao Shen; Yan Luo; Lei Liu; Wenxing Chen; Baoshan Xu; Xiuzhen Han; Jia Pang; Chantal A Rivera; Shile Huang
Journal:  Int J Cancer       Date:  2010-11-15       Impact factor: 7.396

6.  Elevated evolutionary rates in the laboratory strain of Saccharomyces cerevisiae.

Authors:  Zhenglong Gu; Lior David; Dmitri Petrov; Ted Jones; Ronald W Davis; Lars M Steinmetz
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-12       Impact factor: 11.205

7.  Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi.

Authors:  C Borelli; M Schaller; M Niewerth; K Nocker; B Baasner; D Berg; R Tiemann; K Tietjen; B Fugmann; S Lang-Fugmann; H C Korting
Journal:  Chemotherapy       Date:  2008-06-30       Impact factor: 2.544

8.  Impact of the antiproliferative agent ciclopirox olamine treatment on stem cells proteome.

Authors:  Gry H Dihazi; Asima Bibi; Olaf Jahn; Jessica Nolte; Gerhard A Mueller; Wolfgang Engel; Hassan Dihazi
Journal:  World J Stem Cells       Date:  2013-01-26       Impact factor: 5.326

9.  Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity.

Authors:  Siddhartha Sen; Duane C Hassane; Cheryl Corbett; Michael W Becker; Craig T Jordan; Monica L Guzman
Journal:  Exp Hematol       Date:  2013-05-06       Impact factor: 3.084

10.  Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae.

Authors:  Kimberly M Carlson-Banning; Andrew Chou; Zhen Liu; Richard J Hamill; Yongcheng Song; Lynn Zechiedrich
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.